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To evaluate whether the BXLF2 gene of Epstein–Barr virus (EBV), which codes gp85 protein, is essential for infection of
B cells and epithelial cells, we analyzed the infectivity of an EBV recombinant lacking gp85. The cells that were infected with
the BXLF2-disrupted virus were unable to express gp85 proteins that could be detected by mouse monoclonal antibody E1D1,
specific for gp85/gp25 complexes. The BXLF2-disrupted EBV had the ability to attach to, but not infect, B cells. On the other
hand, the same virus failed to bind to and infect NU-GC-3, a human gastric adenocarcinoma cell line that is susceptible to
EBV infection. The results indicate that the gp85 is used for infection of not only B cells but also epithelial cells and suggest
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INTRODUCTION
Epstein–Barr virus (EBV) is a human herpesvirus that
occasionally causes infectious mononucleosis and as-
sociates with lymphoid and epithelioid malignancies
such as Burkitt’s lymphoma, nasopharyngeal carcinoma,
and gastric carcinoma. In vitro, EBV preferentially infects
B cells, owing in large part to restricted expression of the
EBV receptor CD21, which also serves as the receptor for
the complement C3d fragment. The major envelope pro-
tein gp350/220, which is the product of the BLLF1 open
reading frame (ORF), is the ligand that mediates attach-
ment of the virus to CD21 on B cells (Beisel et al., 1985;
Tanner et al., 1987). The envelope of EBV contains many
other glycoproteins that are necessary for infection (Hutt-
Fletcher, 1995). Glycoprotein gp85, which is the product
of the BXLF2 ORF, is the gH homolog of EBV (Heineman
et al., 1988; Oba and Hutt-Fletcher, 1988). It associates
with the gL homologue gp25, which is the product of the
BKLF2 ORF (Yaswen et al., 1993), and gp42, which is
encoded by the BZLF2 ORF (Li et al., 1995). The gp85
complex that consists of gp85, gp25, and gp42 has been
implicated in penetration of the virus into B cells (Miller
and Hutt-Fletcher, 1988; Haddad and Hutt-Fletcher,
1989).
In contrast to B cells, epithelial cells have displayed a
remarkable resistance to EBV infection in vitro (Takada,
1999). Epithelial cells are CD21-negative and this is be-
lieved to be why infection is not established. Recently,
we have shown clear evidence for infection of various
human epithelial cells by EBV in vitro (Yoshiyama et al.,c
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1997; Imai et al., 1998). In that study, most of the epithelial
cell lines that were successfully infected with EBV were
CD21-negative, and the infection was not inhibited by an
anti-CD21 monoclonal antibody (MoAb). The results in-
dicated that EBV infected epithelial cells through a re-
ceptor other than CD21. However, the mechanism of EBV
infection of epithelial cells is largely unknown at present.
In the present study, to evaluate whether the gp85 is
essential for infection of B cells and epithelial cells, we
analyzed the infectivity of an EBV recombinant lacking
gp85. The results indicated that EBV lacking gp85 could
not infect B lymphocytes and epithelial cells.
RESULTS AND DISCUSSION
Comparison of gp85 expression and virus production
between Akata cells harboring the gp851 and gp852
EBV recombinants
We used two EBV recombinants (Fig. 1). One of them
was an insertion-type recombinant in which a neomycin
resistance (neor) gene was inserted into the BXLF1 ORF
ncoding the EBV thymidine kinase (TK) gene, which is
onessential for infection and replication (Shimizu et al.,
996). In this insertion, the BXLF2 gene remained intact.
e used the insertion-type recombinant as a positive
ontrol. The other was a replacement-type recombinant
n which the BXLF1 gene was replaced with the neor
gene (Yoshiyama et al., 1995). The replacement disrupted
he BXLF1 gene and the BXLF2 promoter.
To induce EBV production, both Akata cells infected
ith the insertion-type and the replacement-type EBV
ecombinants were treated with anti-immunoglobulin (Ig)
ntibody and stained by the indirect immunofluores-
ence method with mouse MoAbs C1 (Thorley-Lawson
nd Geilinger, 1980), C30 (unpublished), and E1D1 (Miller
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CKINGand Hutt-Fletcher, 1988) specific for gp350/220, viral
capsid antigen (VCA), and gp85/gp25 complex, respec-
tively. Gp350/220 and VCA were induced in about 40% of
the cells in both cultures. The frequency of E1D1-positive
cells in the cells that were infected with the insertion-
type EBV recombinant was about 25%. In contrast, the
cells that were infected with the replacement-type EBV
recombinant were unable to express the gp85/gp25
complex that could be detected by E1D1 (Fig. 2 and
Table 1). The absence of expression of the gp85/gp25
complex in the replacement-type EBV-infected Akata
cells was also shown by flow cytometric analysis (Fig.
3A). Reverse transcription (RT)-PCR analysis also failed
to detect gp85 mRNA in the Akata cells infected with the
replacement-type EBV recombinant (Fig. 3B). These re-
FIG. 1. Schematic representation of plasmid constructs used to insert
the neor gene into the EBV genome. (A) Insertion-type recombinant
gp851). The 2.1-kb BamHI X fragment that includes the BXLF1 gene
was cloned into the multicloning site of pUC19. The plasmid was
digested with SmaI and treated with calf intestinal alkaline phospha-
tase, and the 1665-bp SalI–EcoRI fragment from pDOL containing the
simian virus 40 promoter-driven neor gene was inserted. When the neor
had recombined into the BXLF1 site, a novel 3.7-kb BamHI fragment
appeared. (B) Replacement-type recombinant (gp852). The 4.3-kb
coRI–HindIII fragment, which includes the BXLF1 gene, was cloned
nto the multicloning site of pBS. The plasmid was digested with AflII
nd treated with calf intestinal alkaline phosphatase. The 1.7-kb AflII
ragment that includes EC-L2, the BXLF2 promoter, was replaced with
he neor gene. When the neor had recombined into the BXLF1 site, a
novel 5.3-kb BamHI fragment appeared.
RECOMBINANT EBV LAsults indicate that the replacement type recombinant is
truly negative for gp85. TNext, we compared the virus production of Akata cells
harboring the replacement-type (gp852) EBV with that of
kata cells harboring the insertion-type (gp851) EBV. In
he three cell clones, gp851 EBV-infected Akata cells
roduced 2.1, 3.3, and 4.7 mg of viral DNA per 1 liter of
ulture supernatant, and gp852 EBV-infected cells pro-
duced 2.0, 2.5, and 4.5 mg of viral DNA per 1 liter of
culture. These results indicate that gp85 plays no role in
assembly and egress.
The gp852 EBV recombinant has the ability to attach
o, but not to infect B cells
Then the infectivity of the gp852 EBV and the gp851
EBV was examined by transformation of cord blood lym-
phocytes and infection of BJAB cells and EBV-negative
Akata cells (Akata2 cells) (Shimizu et al., 1994) (Table 1).
n the gp851 EBV, the 50% transforming dose (TD50) for
cord blood lymphocytes was 105.6/ml. The 50% infection
doses (ID50) for BJAB and Akata
2 cells were 103.3/ml and
103.1/ml, respectively, and the frequencies of EBV-deter-
mined nuclear antigen (EBNA)-positive cells were 22 and
10%, respectively. In the gp852 EBV, however, transfor-
mation of cord blood lymphocytes and the G418-resistant
clones of BJAB and Akata2 cells were not established,
nd transient EBNA expression of these cells was not
etected.
Flow cytometric analysis revealed that both viruses
ere able to bind to B cells similarly (Fig. 4). These
esults indicate that the BXLF2-disrupted EBV recombi-
ant, not expressing gp85, has the ability to attach to B
ells, but not to infect them.
ransfection of the BXLF2 gene restores the ability
f the EBV recombinant lacking glycoprotein gp85
o infect B cells
We examined whether transfection of the BXLF2 gene
estores the ability of the EBV recombinant lacking gp85
o infect B cells. An expression vector that has a cyto-
egalovirus promoter, the hygromycin B resistance
ene, EBNA1, and oriP was transfected into Akata cells
arboring the gp852 EBV by the electroporation method.
After incubation in selective medium containing 400
mg/ml of hygromycin B, hygromycin-B-resistant cell
clones were isolated. In these cell clones, VCA and
gp350 were induced in about 40% of the cells after anti-Ig
treatment. This was not significantly different from the
untransfected cells. The frequency of E1D1-positive cells
after hygromycin B selection was 2.0% (Table 1). We then
evaluated the ability of the virus from the BXLF2-trans-
fected Akata cells harboring gp852 EBV to infect B cells.
The virus succeeded in transforming cord blood lympho-
cytes and lymphoblastoid cell lines were established.
The TD50 for cord blood lymphocytes was 10
3.8/ml. The
53GLYCOPROTEIN gp85ID50 for both BJAB and Akata
2 cells was 100.6/ml. The
D50 and ID50 of the virus were low compared with that of
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ecombgp851 EBV (Table 1), possibly because the frequency of
E1D1-positive cells of the cells transfected with BXLF2
was low. Southern blot analysis showed that the lympho-
blastoid cell lines were infected with gp852 EBV (Fig. 5).
These results provide direct evidence that gp85, the
BXLF2 gene product, is essential for infection of B cells.
The gp852 EBV recombinant cannot bind to and
nfect epithelial cells either
To determine whether the BXLF2 gene was necessary
FIG. 2. Indirect immunofluorescence staining by MoAb E1D1, specific
IgG1 as isotype control (E, F). Akata cells harboring the insertion-type r
EBV (B, D, F).
54 ODor infection of epithelial cells, we examined the infectiv-
ty of the gp852 EBV recombinant to NU-GC-3, a humanastric adenocarcinoma cell line that was susceptible to
BV infection but negative for CD21 expression (Imai et
l., 1998). The cells were seeded into a 12-well plate at
3 104/well 2 days before infection. On the day of
infection, all culture medium was replaced with 2 ml of
fresh medium, and 1 ml of virus supernatant was added
to the culture. Virus concentrations were adjusted to be
equal as judged by the measurement of virus DNA. Four
days after infection, the cells were reseeded into 24-well
plates at 5 3 104/well in culture medium containing 700
85/gp25 complex (A, B), MoAb C1, specific for gp350 (C, D), and mouse
inant (gp851) EBV (A, C, E) and replacement-type recombinant (gp852)
L.for gp
A ET Amg/ml of G418. G418-resistant cells were obtained with
the gp851 EBV recombinant in half of the wells (37/72
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resistant cells was obtained with the gp852 EBV recom-
binant (0/72 wells). Next, we employed a cocultivation
method as a more effective infection procedure (Imai et
al., 1998). Gp851 or gp852 EBV-infected Akata cells (5 3
105/well) treated with anti-Ig were added to the culture of
U-GC-3 cells. After completion of the infection step (day
), the virus donor cells were washed out. On day 4 the
nfected cells were seeded into 24-well plates at 2 3
04/well in medium containing G418. Resistant cells were
T
Comparison of Antigen Expression and Infectiv
the gp851 and gp
Source of EBV
Antigen-positive cells (%
gp350/220b VCAb
gp851 EBVc 41 40
gp852 EBVd 44 38
p852 EBV 1 BXLF2e 36 37
a Akata cells infected with each EBV recombinant were treated with
b Gp350/220, VCA, and gp85/25 were detected by MoAbs C1, C30, a
c Akata cells harboring the insertion-type recombinant in which a Ne
sed as positive controls.
d Akata cells harboring the replacement-type recombinant in which
disrupted in the replacement.
e Transfectant of BXLF2 into Akata cells harboring the replacement-
FIG. 3. Gp85 expression in Akata cells harboring the insertion-type
and replacement-type EBV recombinants. (A) Two-color flow cytometric
RECOMBINANT EBV LAanalysis of gp85/gp25 and gp350/220 expression. (B) RT-PCR analysis
of gp85 mRNA.btained with the gp851 EBV recombinant in all of the
ells (72/72 wells). Nevertheless, there were none with
he gp852 EBV recombinant (0/72 wells). The results
indicate that the gp85 is used for infection of not only B
cells but also epithelial cells. We failed to demonstrate
that transfection of the BXLF2 gene complemented the
infectivity of gp852 EBV in epithelial cells as with B-cell
nfection, possibly because the efficacy of infection was
ower in epithelial cells than in B cells.
We examined the ability of gp852 and gp851 EBV
ecombinants to bind to epithelial cells with the same
ethods that were employed for B cells. Flow cytometric
nalysis showed that gp852 EBV could not bind to, or if
it did, had a very low affinity to NU-GC-3 cells (Fig. 4).
This result indicates the possibility that the gp85/25
complex is the ligand for attaching the virus to epithelial
cells.
We present here direct evidence that gp85 is essential
for infection of B cells and epithelial cells. It has been
thought that the gp85/gp25/gp42 complex plays an im-
portant role in the infection of B cells by EBV. The MoAb
to gp42, called F-2-1, inhibits the ability of the virus to
infuse into the B cells (Miller and Hutt-Fletcher, 1988).
Glycoprotein gp42 is essential for infection of B cells and
is thought to bind to HLA-DR and to bring the attached
virus particle closer to the cell membrane than does the
initial interaction between gp350 and CD21 (Li et al.,
1997). Wang and Hutt-Fletcher (1998) proved that gp42 is
essential for penetration of the B-cell membrane but not
of epithelial cells, using a BZLF2-disrupted EBV recom-
binant. Recently, Wang and colleagues (1998) showed
that a soluble form of gp42, which interacts with gp85/25,
could inhibit infection of epithelial cell line SVKCR2 ex-
roduced Virus between Akata Cells Harboring
V Recombinantsa
Infectivity of produced virus
TD50/ml ID50/ml
5/25b Cord lymphocyte BJAB Akata2
25 105.6 103.3 103.1
0 0 0 0
2 103.8 100.6 100.6
.
1, respectively.
is inserted into the BXLF1 ORF encoding the EBV TK gene. They were
XLF1 gene is replaced with the Neor gene. The BXLF2 promoter is
combinant (gp852) EBV.
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model in which EBV virions contain two types of gp85
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acomplex. The tripartite complex that includes gp42 is
used for infection of B cells and the bipartite complex
that does not include gp42 is used for infection of epi-
thelial cells. This model is fits well with the observation
that MoAb E1D1, which reacts with the bipartite complex
(possibly at the gp42 binding site of gp85/gp25 complex)
in the absence of gp42, has no effect on B-cell infection
but neutralizes the infection of epithelial cells (Li et al.,
1995). Of the three glycoproteins, gp85, which has the
most hydrophobic characteristics for disruption of the
lipid bilayer (Oba and Hutt-Fletcher, 1988), seems to be a
major player. On the other hand, it is supposed that gp25
is an indispensable partner that is required to transport
the gp85/gp25 complex to the cell surface (Li et al., 1995).
Our experiment suggest that EBV utilizes the gp85
complex for binding to epithelial cells, although it is not
known whether the gp85 directly interacts with the re-
FIG. 4. The ability of gp852 ( ) or gp851 (—) EBV to bind to the
ITC-conjugated anti-mouse Ig as a negative control. An SKN cell, CD
FIG. 5. Southern blot analysis. Ten micrograms of cellular DNA was
digested with BamHI, blotted, and hybridized with the neor or BamHI X
probe by a procedure described previously (Yoshiyama et al., 1995) The
BamHI X probe identified a 2.1-kb fragment in wild EBV-infected Akata
cells, a 3.7-kb fragment in gp851 EBV-infected Akata cells and LCL, and
56 ODa 5.3-kb fragment in gp852 EBV-infected Akata cells and LCL. The 3.7-
nd 5.3-kb bands also hybridized to the neor probe (see Fig. 1).ceptor molecules. The identification of the molecule on
epithelial cells that interacts with the gp85 complex will
be a subject for further study.
MATERIALS AND METHODS
Cell lines, cell culture, and induction
of virus replication
The Akata cell line (Takada, 1984) is derived from an
EBV-positive Burkitt’s lymphoma and expresses surface
Ig of the G, kappa class. The Akata cell line was sub-
cloned and 100% EBV-positive Akata clones and com-
pletely EBV-negative Akata clones (Akata2) were isolated
Shimizu et al., 1994). BJAB is an EBV-negative B-lym-
homa line that expresses CD21. NU-GC-3 is a human
astric adenocarcinoma cell line (Akiyama et al., 1988)
hat is susceptible for EBV infection, but is negative for
D21 expression (Imai et al., 1998). All cells were main-
ained in RPMI 1640 medium supplemented with 10%
etal bovine serum (Gibco), penicillin (40 U/ml), and
treptomycin (280 mg/ml) at 37°C in a 5% humidified CO2
atmosphere.
To induce EBV production in Akata cells, 5 3 106 cells
were incubated in 5 ml of complete medium containing
0.5% (v/v) rabbit antibodies specific for human IgG (Dako)
for 48 h.
Titration of EBV infectivity
The infectivity of EBV was examined by transformation
of cord blood lymphocytes and infection of BJAB and
Akata2 cells. For the transformation assay, cells (2 3 106)
ere incubated with 1 ml of serially diluted EBV suspen-
ion for 60 min. Then, cells were washed, resuspended
n 1 ml of fresh medium, and transferred to 96-well plates
200 ml/well). The cultures were fed weekly by changing
half of the medium and observed on an inverted micro-
scope every 5 days for 6 weeks to detect the appearance
of growing cell aggregates. The demonstration of EBNA
in the transformed cells was taken as proof of the role of
EBV in the transformation. The infectivity of BJAB and
(Akata) and epithelial cell (NU-GC-3) surface. (. . .) Cells treated with
ative T-cell line is used as a negative control.
L.A ET AAkata2 cells was assayed by appearance of G418-resis-
tant cell clones. Cells (1.25 3 105) were incubated with 1
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CKINGml of serially diluted EBV suspension for 60 min. Then,
cells were washed, resuspended in 1.2 ml of fresh me-
dium, and incubated for 1 day. Then, cells were resus-
pended in 1.2 ml of fresh medium containing G418 (1
mg/ml) and transferred to 96-well plates (200 ml/well).
The cultures were fed every 5 days by changing half of
the medium and observed for 6 weeks to detect the
appearance of G418-resistant cell clones. The TD50 and
ID50 were calculated by the Reed–Muench formula.
etection of EBV antigens
Cell smears were dried and fixed in acetone–methanol
1:1) for 2 min. EBNA was detected by the anticomple-
ent immunofluorescence method with human immune
erum (EBNA titer of 1:1280). Gp350/220, viral capsid
ntigen, and gp85/gp25 complex were detected by the
ndirect immunofluorescence method with mouse mono-
lonal antibodies C1, C30, and E1D1, respectively.
low cytometric analysis
For the dual detection of gp85/gp25 complex and
p350/220, cells (2 3 105) were washed with cold phos-
hate-buffered saline (PBS) containing 2% fetal bovine
erum and serially reacted with MoAb E1D1, PRE-conju-
ated anti-mouse Ig (Dako), mouse IgG1 (Dako), and
ITC-conjugated anti-gp350/220 (Virostat) with washing
etween each step, followed by flow cytometric analysis
n a FACScan (Becton–Dickinson).
T-PCR
RT-PCR analysis was carried out to investigate the
xpression of gp85 in recombinant EBV-infected Akata
ells. Total cellular RNA was isolated by guanidium iso-
hiocyanate–phenol extraction using TRIzol reagent
Gibco BRL) according to the manufacturer’s protocol.
NA was solubilized in distilled water, treated with
Nase I (Gibco BRL) at 37°C for 15 min. For reverse
ranscription, 1 mg of total RNA was denatured at 94°C
for 10 min in the presence of 10 pmol of oligo dT primer
(Takara, Otsu, Japan), chilled on ice, and incubated with
Molony murine leukemia virus reverse transcriptase
(RTase, GIBCO BRL) at 37°C for 1 h, followed by 10 min
of heating at 94°C to inactivate RTase. The cDNA sam-
ples were then subjected to 30 cycles of PCR in a
thermal cycler. Each cycle consisted of denaturation for
15 s at 94°C, annealing for 15 s at 50°C, and extension
for 30 s at 72°C. The reaction mixture contained buffers
and reagents with 20 pmol of each primer (59 TTACCAG-
GACGCAGAAATCC 39 and 59 TGCCAAAACAACGTGT-
GCTC 39) and cDNA (corresponding to 100 ng of total
RNA) in a volume of 50 ml. Five microliters of the PCR
roducts was electrophoresed in 2% agarose gels. The
RECOMBINANT EBV LAuality of RNA was checked by parallel amplification of
b-actin mRNA.Virus purification and measurement of viral DNA
Virus was purified from the supernatants of Akata
culture according to the method of Dolyniuk et al. (1976).
Viral DNA was obtained from purified virus preparations
by lysis in 1% sodium dodecyl sulfate (SDS) and phenol
extraction. Viral DNA was digested with BamHI, sepa-
rated by electrophoresis in 0.8% agarose gels, and
stained with SYBR Green (Molecular Probes). The
amount of viral DNA was estimated from the intensity of
DNA bands using a fluoroimage analyzer (FLA-2000,
Fujifilm).
Virus binding assay
To examine the ability of virus to bind to the cell
surface, cells (5 3 105) were incubated with 100 ml of
purified virus suspension (corresponding to 25 ng of viral
DNA) at 4°C for 2 h. After three washes with ice-cold
medium, the cells were incubated with MoAb C1 for 30
min. Then, they were washed with ice-cold PBS, treated
with FITC-conjugated anti-mouse Ig, and analyzed by
flow cytometry.
Transfection of BXLF2 gene
A 2.4-kb NheI fragment containing the BXLF2 ORF was
cloned into the NheI site in the multicloning site of
pCEP4, an expression vector that has a cytomegalovirus
promoter, the hygromycin B resistance gene, EBNA1, and
oriP. The pCEP4-BXLF2 plasmid was transfected into
Akata cells harboring the gp852 EBV by the electropora-
ion method. After incubation in ordinary culture medium
or 2 days, the cells were transferred to selective medium
ontaining 400 mg/ml of hygromycin B.
Southern blot analysis
Purified cellular DNA (10 mg) was digested with
amHI, size fractionated by electrophoresis in a 0.7%
garose gel, and transferred to a nylon membrane (Hy-
ond N1; Amersham). Probe DNAs were labeled with
a32P]dCTP (3000 Ci/ml) by random priming. Hybridiza-
tion was performed at 42°C overnight in 50% form-
amide–53 Denhardt’s solution–53 SSC (13 SSC is 0.15
M NaCl plus 0.015 M sodium citrate)–0.5% SDS contain-
ing salmon testis DNA (100 mg/ml; Sigma). After hybrid-
ization, the membranes were washed twice in 13 SSC–
0.1% SDS for 5 min each at room temperature and once
in 0.13 SSC–0.1% SDS for 10 min at 55°C. Autoradiogra-
phy was done overnight at 280°C.
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